Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE) February 19, 2021 -- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news